AR043547A1 - Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales - Google Patents
Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinalesInfo
- Publication number
- AR043547A1 AR043547A1 ARP040100781A ARP040100781A AR043547A1 AR 043547 A1 AR043547 A1 AR 043547A1 AR P040100781 A ARP040100781 A AR P040100781A AR P040100781 A ARP040100781 A AR P040100781A AR 043547 A1 AR043547 A1 AR 043547A1
- Authority
- AR
- Argentina
- Prior art keywords
- rifaximin
- water
- temperature
- crude
- ethyl alcohol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B6/00—Heating by electric, magnetic or electromagnetic fields
- H05B6/02—Induction heating
- H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
- H05B6/12—Cooking devices
- H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
- H05B6/1236—Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05B—ELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
- H05B6/00—Heating by electric, magnetic or electromagnetic fields
- H05B6/02—Induction heating
- H05B6/10—Induction heating apparatus, other than furnaces, for specific applications
- H05B6/12—Cooking devices
- H05B6/1209—Cooking devices induction cooking plates or the like and devices to be used in combination with them
- H05B6/1245—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
- H05B6/1263—Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements
Abstract
Formas cristalinas polimórficas del antibiótico rifaximina (INN) denominadas rifaximina a y rifaximina b y una forma pobremente cristalina denominada rifaximina g. Estas formas son de utilidad en la producción de preparaciones medicinales para uso por vía oral y tópica y se pueden obtener por medio de un proceso de cristalización llevado a cabo por disolución en caliente de la rifaximina cruda en alcohol etílico y por cristalización del producto mediante la adición de agua a una temperatura determinada y por un período de tiempo determinado. La cristalización es seguida de un secado llevado a cabo bajo condiciones controladas hasta alcanzar un contenido de agua específico en el producto final. Reivindicación 1: Una rifaximina alfa purificada, un polimorfo del antibiótico rifaximina, caracterizada porque dicha rifaximina alfa presenta un contenido de agua menor que un 4,5% y produce un difractograma de polvo por rayos X que presenta picos en valores de ángulos de difracción 2theta de 6,6s, 7,4s; 7,9s; 8,8s; 10,5s; 11,1s; 11,8s; 12,9s; 17,6s; 18,5s; 19,7s; 21,0s; 21,4s; 22,1s. Reivindicación 6: Un proceso para la producción de las rifaximinas alfa, beta y gamma, caracterizado porque comprende: hacer reaccionar un equivalente molar de rifaximina O con un exceso de 2-amino-4-metilpiridina en una mezcla de solventes compuesta de agua y alcohol etílico en una relación volumétrica que comprende entre 1:1 y 2:1, por un período de tiempo entre 2 y 8 horas, a una temperatura entre 40sC y 60sC, tratar la masa de reacción a temperatura ambiente con una solución de ácido ascórbico en una mezcla de agua, alcohol etílico y ácido clorhídrico acuoso concentrado, ajustar el pH de la masa de reacción en pH 2,0 con una solución acuosa concentrada de ácido clorhídrico, filtrar la suspensión, lavar todo sólido resultante con la mezcla de solventes de agua/alcohol etílico para obtener una rifaximina cruda, purificar la rifaximina cruda por disolución de la misma en alcohol etílico a una temperatura que comprende entre 45sC y 65sC, hacer precipitar la rifaximina cruda por adición de agua y por disminución de la temperatura de la suspensión a un valor entre 0sC y 50sC bajo agitación por un período de tiempo entre 4 y 36 horas, filtrar la suspensión, lavar el sólido resultante con agua, y secarlo bajo vacío o bajo condiciones de presión normal, con o sin un agente de secado, a una temperatura entre temperatura ambiente y 105sC, por un período de tiempo entre 2 y 72 horas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT002144A ITMI20032144A1 (it) | 2003-11-07 | 2003-11-07 | Forme polimorfe di rifaximina, processi per ottenerle e |
Publications (1)
Publication Number | Publication Date |
---|---|
AR043547A1 true AR043547A1 (es) | 2005-08-03 |
Family
ID=33187382
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040100781A AR043547A1 (es) | 2003-11-07 | 2004-03-11 | Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales |
ARP110102194A AR081992A2 (es) | 2003-11-07 | 2011-06-23 | FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS |
ARP110102193A AR081991A2 (es) | 2003-11-07 | 2011-06-23 | FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP110102194A AR081992A2 (es) | 2003-11-07 | 2011-06-23 | FORMA POLIMORFICA g DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS |
ARP110102193A AR081991A2 (es) | 2003-11-07 | 2011-06-23 | FORMA POLIMORFICA b DE RIFAXIMINA, PROCESOS PARA SU PRODUCCION Y SUS COMPOSICIONES FARMACEUTICAS |
Country Status (38)
Country | Link |
---|---|
US (5) | US7045620B2 (es) |
EP (6) | EP1676848B1 (es) |
JP (5) | JP2005139161A (es) |
KR (4) | KR20050043589A (es) |
CN (4) | CN1613858A (es) |
AR (3) | AR043547A1 (es) |
AT (3) | ATE421966T1 (es) |
AU (2) | AU2004200964A1 (es) |
BR (2) | BRPI0402382A (es) |
CA (2) | CA2460384A1 (es) |
CL (1) | CL2004000498A1 (es) |
CO (1) | CO5560083A1 (es) |
CY (3) | CY1108017T1 (es) |
DE (4) | DE602004019298D1 (es) |
DK (3) | DK1676848T3 (es) |
ES (3) | ES2320161T3 (es) |
HK (3) | HK1092150A1 (es) |
HR (2) | HRP20040265A2 (es) |
IL (2) | IL160798A0 (es) |
IT (1) | ITMI20032144A1 (es) |
JO (1) | JO2470B1 (es) |
MA (1) | MA27069A1 (es) |
MD (1) | MD3653G8 (es) |
ME (1) | ME00424B (es) |
MX (2) | MXPA04002353A (es) |
NO (1) | NO334950B1 (es) |
NZ (1) | NZ531622A (es) |
PL (3) | PL1557421T3 (es) |
PT (3) | PT1676847E (es) |
RS (4) | RS54569B1 (es) |
RU (1) | RU2270200C2 (es) |
SI (3) | SI1676847T1 (es) |
TN (2) | TNSN04044A1 (es) |
TW (1) | TWI285107B (es) |
UA (1) | UA86384C2 (es) |
WO (1) | WO2005044823A2 (es) |
YU (1) | YU24804A (es) |
ZA (1) | ZA200401948B (es) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6861053B1 (en) * | 1999-08-11 | 2005-03-01 | Cedars-Sinai Medical Center | Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth |
US7048906B2 (en) * | 1995-05-17 | 2006-05-23 | Cedars-Sinai Medical Center | Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20080262024A1 (en) * | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US7906542B2 (en) * | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
US7902206B2 (en) * | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7923553B2 (en) * | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
EP1698630B1 (en) * | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
JP5844961B2 (ja) | 2006-08-02 | 2016-01-20 | サリックス ファーマシューティカルズ, インコーポレイテッド | 放射線直腸s状結腸炎を処置するための組成物および方法 |
ITMI20061692A1 (it) | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
KR101667534B1 (ko) * | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
US20080159987A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Restless Legs Syndrome |
US20080161337A1 (en) * | 2007-01-03 | 2008-07-03 | Leonard Weinstock | Use of Rifaximin for the Treatment of Chronic Prostatitis |
ITMI20071241A1 (it) * | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
WO2009008005A1 (en) * | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
ES2798253T3 (es) * | 2007-07-06 | 2020-12-10 | Lupin Ltd | Composiciones farmacéuticas de rifaximina |
AU2016203925B2 (en) * | 2007-07-06 | 2016-10-20 | Lupin Limited | Pharmaceutical compositions of rifaximin |
US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
SG188931A1 (en) | 2008-02-25 | 2013-04-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
KR20100122937A (ko) | 2008-02-26 | 2010-11-23 | 샐릭스 파마슈티컬스 리미티드 | 장 질환의 치료 방법 |
AU2009244190B2 (en) | 2008-05-07 | 2016-02-25 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
CN102164599B (zh) | 2008-09-26 | 2014-07-23 | Aska制药株式会社 | 预防和/或治疗功能性胃肠障碍的药剂 |
US7928115B2 (en) * | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US20100317681A1 (en) * | 2009-06-15 | 2010-12-16 | Salix Pharmaceuticals, Ltd. | Modulation of systemic exposure to rifaximin |
DK2350096T3 (da) * | 2008-10-02 | 2020-03-02 | Salix Pharmaceuticals Ltd | Fremgangsmåder til behandling af hepatisk encephalopati |
KR20110107806A (ko) | 2008-12-10 | 2011-10-04 | 시플라 리미티드 | 리팍시민 복합체 |
IT1397617B1 (it) * | 2009-04-20 | 2013-01-18 | Alfa Wassermann Spa | Nuovi derivati della rifamicina |
KR20120025578A (ko) * | 2009-06-02 | 2012-03-15 | 샐릭스 파마슈티컬스 리미티드 | 간성 뇌병증의 치료방법 |
EP2475392A4 (en) * | 2009-09-13 | 2013-01-09 | Salix Pharmaceuticals Ltd | METHOD FOR TREATING IRRITATION SYNDROME |
KR20140015140A (ko) * | 2009-10-27 | 2014-02-06 | 루핀 리미티드 | 리팍시민의 고형 분산물 |
WO2011061748A1 (en) * | 2009-11-19 | 2011-05-26 | Strides Arcolab Limited | Rifaximin premix |
WO2011061519A2 (en) | 2009-11-23 | 2011-05-26 | Cipla Limited | Topical foam composition |
US8952159B2 (en) | 2009-12-28 | 2015-02-10 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
AU2011218129A1 (en) | 2010-02-18 | 2012-08-23 | Board Of Regents Of The University Of Texas System | Methods for treating infection |
IT1398550B1 (it) | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
JP2013527246A (ja) * | 2010-06-03 | 2013-06-27 | サリックス ファーマシューティカルズ リミテッド | リファキシミンの型およびその使用 |
WO2011156897A2 (en) * | 2010-06-16 | 2011-12-22 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
MY165086A (en) | 2010-07-12 | 2018-02-28 | Salix Pharmaceuticals Ltd | Formulations of rifaximin and uses thereof |
US8759513B2 (en) | 2010-09-13 | 2014-06-24 | Sequent Scientific Limited | Polymorphic form of rifaximin and process for its preparation |
IT1403847B1 (it) * | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
WO2012060675A1 (es) * | 2010-11-05 | 2012-05-10 | Interquim, S.A. De C.V. | Proceso para la preparación de rifaximina amorfa |
WO2012076832A1 (en) * | 2010-12-09 | 2012-06-14 | Cipla Limited | Suppositories comprising rifaximin |
JP6076267B2 (ja) | 2011-02-11 | 2017-02-08 | サリックス ファーマスーティカルズ,リミテッド | リファキシミンの形態およびその使用 |
CA2834829A1 (en) | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
ITMI20110890A1 (it) * | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
EP2773205A4 (en) * | 2011-11-02 | 2015-03-25 | Salix Pharmaceuticals Ltd | METHOD FOR TREATING IRRITATION SYNDROME AND INFECTIONS |
JP2013184902A (ja) * | 2012-03-06 | 2013-09-19 | Aska Pharmaceutical Co Ltd | リファキシミン含有結晶 |
US9359374B2 (en) | 2012-06-13 | 2016-06-07 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014091432A1 (en) | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
EP2971062A2 (en) | 2013-03-15 | 2016-01-20 | ALFA WASSERMANN S.p.A. | Method for diagnosing vaginal infections |
MX2015011802A (es) | 2013-03-15 | 2016-01-08 | Alfa Wassermann Spa | Rifaximina para usarse en el tratamiento de infecciones vaginales. |
US20140308350A1 (en) | 2013-04-12 | 2014-10-16 | Alfa Wassermann S.P.A. | Nsaid administration and related compositions, methods and systems |
US9018225B1 (en) | 2013-07-26 | 2015-04-28 | Novel Laboratories | Rifaximin crystalline forms and methods of preparation thereof |
ES2621557T3 (es) | 2014-03-31 | 2017-07-04 | Euticals S.P.A. | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas |
US9765088B2 (en) | 2014-04-19 | 2017-09-19 | Granules India Limited | Process for the preparation of rifamycin derivatives |
WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
PL3546464T3 (pl) | 2014-05-12 | 2020-11-02 | Alfasigma S.P.A. | Sposób wytwarzania i zastosowanie postaci krystalicznej Tau rifaksyminy solwatowanej z DEGME |
MX2016016458A (es) * | 2014-06-30 | 2017-07-13 | Salix Pharmaceuticals Inc | Métodos para repetir tratamiento de síndrome del intestino irritable (ibs). |
CN104083324B (zh) * | 2014-07-10 | 2017-05-10 | 青岛动保国家工程技术研究中心有限公司 | 一种利福昔明的兽用悬乳剂及其制备方法和应用 |
EP2982764A1 (en) | 2014-08-05 | 2016-02-10 | ALFA WASSERMANN S.p.A. | Identification of vaginal bacteria |
CN104274391B (zh) * | 2014-10-08 | 2017-02-01 | 哈尔滨坤盟医药科技有限公司 | 一种含利福昔明的药物制剂 |
WO2017021975A1 (en) * | 2015-08-06 | 2017-02-09 | Msn Laboratories Private Limited | Process for the preparation of crystalline forms of rifaximin |
EP3536311B1 (en) | 2016-03-24 | 2021-12-22 | Sandoz AG | Storage stable composition comprising rifaximin alpha |
HUE056045T2 (hu) | 2016-03-24 | 2022-01-28 | Sandoz Ag | Rifaximin alfa és delta tartalmú gyógyászati készítmény |
US9988398B2 (en) * | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
ES2929768T3 (es) | 2016-09-30 | 2022-12-01 | Salix Pharmaceuticals Inc | Formas sólidas de dispersión de rifaximina |
CN106632396B (zh) * | 2017-01-06 | 2019-01-11 | 成都樵枫科技发展有限公司 | γ晶型利福昔明的制备方法和用途 |
US11052071B2 (en) * | 2017-04-26 | 2021-07-06 | Sandoz Ag | Oral dosage form comprising rifaximin in form beta |
RU2020102511A (ru) | 2017-06-26 | 2021-07-27 | Биофер С.П.А. | Соединения пиридо-имидазо рифамицина в качестве антибактериального средства |
CA3142214A1 (en) | 2019-06-03 | 2020-12-10 | Bausch Health Ireland Limited | Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders |
JP2022548788A (ja) | 2019-09-24 | 2022-11-21 | バウシュ ヘルス アイルランド リミテッド | リファキシミン液体製剤 |
WO2021191312A1 (en) | 2020-03-24 | 2021-09-30 | Bausch Health Ireland Limited | Methods of treating covid-19 with rifaximin |
WO2021229480A1 (en) * | 2020-05-15 | 2021-11-18 | Atra Pharmaceuticals Limited | Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin |
US20230277447A1 (en) | 2020-06-26 | 2023-09-07 | Bausch Health Ireland Limited | Targeted release rifaximin compositions |
US20230398102A1 (en) | 2020-10-29 | 2023-12-14 | Bausch Health Ireland Limited | Rifaximin liquid formulations for use inthe treatment of sickle cell disease |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4241785A (en) * | 1978-07-24 | 1980-12-30 | Peerless Of America, Inc. | Heat exchangers and method of making same |
IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
CA1215976A (en) | 1984-05-15 | 1986-12-30 | Vincenzo Cannata | New process for the synthesis of imidazo rifamycins |
IT1199413B (it) | 1984-09-26 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
GB8816620D0 (en) * | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
EP0536197B1 (en) * | 1990-06-29 | 1995-07-26 | GRUPPO LEPETIT S.p.A. | Pure crystalline form of rifapentine |
WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
UA75365C2 (en) * | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
WO2002036542A1 (en) * | 2000-10-31 | 2002-05-10 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of venlafaxine hydrochloride |
IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20050262269A1 (en) | 2004-05-20 | 2005-11-24 | Pike Jimmy D | System and method for information handling system PCI express advanced switching |
EP1698630B1 (en) | 2005-03-03 | 2014-09-03 | ALFA WASSERMANN S.p.A. | New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations |
KR101667534B1 (ko) * | 2006-09-22 | 2016-10-19 | 씨아이피엘에이 엘티디. | 리팍시민 |
WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
ES2798253T3 (es) | 2007-07-06 | 2020-12-10 | Lupin Ltd | Composiciones farmacéuticas de rifaximina |
WO2009008005A1 (en) | 2007-07-06 | 2009-01-15 | Lupin Limited | Pharmaceutical compositions of rifaximin |
US7709634B2 (en) * | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
JP2011500552A (ja) | 2007-10-10 | 2011-01-06 | ルピン・リミテッド | 胃腸障害を処置するための医薬用組み合わせおよび組成物 |
SG188931A1 (en) | 2008-02-25 | 2013-04-30 | Salix Pharmaceuticals Ltd | Forms of rifaximin and uses thereof |
-
2003
- 2003-11-07 IT IT002144A patent/ITMI20032144A1/it unknown
- 2003-12-05 US US10/728,090 patent/US7045620B2/en active Active
-
2004
- 2004-03-09 PT PT06004219T patent/PT1676847E/pt unknown
- 2004-03-09 PT PT04005541T patent/PT1557421E/pt unknown
- 2004-03-09 DK DK06004220T patent/DK1676848T3/da active
- 2004-03-09 DK DK04005541T patent/DK1557421T3/da active
- 2004-03-09 SI SI200431074T patent/SI1676847T1/sl unknown
- 2004-03-09 ES ES06004220T patent/ES2320161T3/es not_active Expired - Lifetime
- 2004-03-09 PT PT06004220T patent/PT1676848E/pt unknown
- 2004-03-09 PL PL04005541T patent/PL1557421T3/pl unknown
- 2004-03-09 AT AT06004220T patent/ATE421966T1/de active
- 2004-03-09 DE DE602004019298T patent/DE602004019298D1/de not_active Expired - Lifetime
- 2004-03-09 AT AT06004219T patent/ATE421965T1/de active
- 2004-03-09 PL PL06004220T patent/PL1676848T3/pl unknown
- 2004-03-09 ES ES06004219T patent/ES2320160T4/es not_active Expired - Lifetime
- 2004-03-09 AT AT04005541T patent/ATE361927T1/de active
- 2004-03-09 DE DE04005541T patent/DE04005541T1/de active Pending
- 2004-03-09 NZ NZ531622A patent/NZ531622A/en not_active IP Right Cessation
- 2004-03-09 EP EP06004220A patent/EP1676848B1/en not_active Expired - Lifetime
- 2004-03-09 IL IL16079804A patent/IL160798A0/xx unknown
- 2004-03-09 EP EP06004219A patent/EP1676847B1/en not_active Expired - Lifetime
- 2004-03-09 ES ES04005541T patent/ES2244364T3/es not_active Expired - Lifetime
- 2004-03-09 DK DK06004219T patent/DK1676847T3/da active
- 2004-03-09 PL PL06004219T patent/PL1676847T3/pl unknown
- 2004-03-09 DE DE602004019296T patent/DE602004019296D1/de not_active Expired - Lifetime
- 2004-03-09 SI SI200431070T patent/SI1676848T1/sl unknown
- 2004-03-09 SI SI200430297T patent/SI1557421T1/sl unknown
- 2004-03-09 CA CA002460384A patent/CA2460384A1/en not_active Abandoned
- 2004-03-09 EP EP04005541A patent/EP1557421B1/en not_active Expired - Lifetime
- 2004-03-09 DE DE602004006367.3T patent/DE602004006367C5/de not_active Expired - Lifetime
- 2004-03-10 ZA ZA200401948A patent/ZA200401948B/xx unknown
- 2004-03-10 AU AU2004200964A patent/AU2004200964A1/en not_active Abandoned
- 2004-03-11 MX MXPA04002353A patent/MXPA04002353A/es unknown
- 2004-03-11 CO CO04022467A patent/CO5560083A1/es not_active Application Discontinuation
- 2004-03-11 AR ARP040100781A patent/AR043547A1/es not_active Application Discontinuation
- 2004-03-11 CL CL200400498A patent/CL2004000498A1/es unknown
- 2004-03-16 TW TW093106943A patent/TWI285107B/zh active
- 2004-03-16 CN CNA2004100477623A patent/CN1613858A/zh active Pending
- 2004-03-17 JP JP2004076458A patent/JP2005139161A/ja active Pending
- 2004-03-17 KR KR1020040017892A patent/KR20050043589A/ko not_active Application Discontinuation
- 2004-03-18 HR HRP20040265 patent/HRP20040265A2/hr not_active Application Discontinuation
- 2004-03-18 RU RU2004108953/04A patent/RU2270200C2/ru active
- 2004-03-18 JO JO200433A patent/JO2470B1/en active
- 2004-03-19 YU YU24804A patent/YU24804A/sh unknown
- 2004-03-19 TN TNP2004000044A patent/TNSN04044A1/en unknown
- 2004-03-19 BR BR0402382-0A patent/BRPI0402382A/pt not_active IP Right Cessation
- 2004-03-24 MA MA27590A patent/MA27069A1/fr unknown
- 2004-04-11 UA UAA200602354A patent/UA86384C2/uk unknown
- 2004-11-04 RS RS20150291A patent/RS54569B1/en unknown
- 2004-11-04 RS RS20150292A patent/RS54571B1/en unknown
- 2004-11-04 ME MEP-2008-633A patent/ME00424B/me unknown
- 2004-11-04 RS YUP-2006/0168A patent/RS20060168A/sr unknown
- 2004-11-04 KR KR1020077026410A patent/KR100867751B1/ko active IP Right Grant
- 2004-11-04 CN CN2008100869308A patent/CN101260114B/zh active Active
- 2004-11-04 RS RS20060168A patent/RS54568B1/en unknown
- 2004-11-04 MX MXPA06002644A patent/MXPA06002644A/es active IP Right Grant
- 2004-11-04 CN CN2004800030228A patent/CN1886408B/zh active Active
- 2004-11-04 WO PCT/EP2004/012490 patent/WO2005044823A2/en active Application Filing
- 2004-11-04 BR BRPI0407149A patent/BRPI0407149A8/pt not_active Application Discontinuation
- 2004-11-04 AU AU2004287601A patent/AU2004287601B8/en active Active
- 2004-11-04 CN CN2008100869327A patent/CN101260115B/zh active Active
- 2004-11-04 CA CA2538546A patent/CA2538546C/en active Active
- 2004-11-04 KR KR1020057013910A patent/KR100855084B1/ko active IP Right Review Request
- 2004-11-04 EP EP10004589A patent/EP2210893A1/en not_active Withdrawn
- 2004-11-04 KR KR1020077026409A patent/KR100883216B1/ko active IP Right Grant
- 2004-11-04 EP EP10004590A patent/EP2208730A1/en not_active Withdrawn
- 2004-11-04 MD MDA20060080A patent/MD3653G8/ro active IP Right Grant
- 2004-11-04 EP EP04797615A patent/EP1682556A2/en not_active Withdrawn
- 2004-11-04 JP JP2006537252A patent/JP5199576B2/ja active Active
-
2005
- 2005-05-24 US US11/135,651 patent/US20050272754A1/en not_active Abandoned
- 2005-08-04 HK HK06113863.1A patent/HK1092150A1/xx not_active IP Right Cessation
- 2005-08-04 HK HK06113864.0A patent/HK1092151A1/xx not_active IP Right Cessation
- 2005-08-04 HK HK05106702A patent/HK1073657A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 TN TNP2006000069A patent/TNSN06069A1/en unknown
- 2006-03-08 NO NO20061110A patent/NO334950B1/no unknown
- 2006-03-08 HR HRP20060093AA patent/HRP20060093B1/hr active IP Right Grant
- 2006-03-12 IL IL174271A patent/IL174271A/en active IP Right Grant
-
2007
- 2007-07-02 CY CY20071100875T patent/CY1108017T1/el unknown
- 2007-10-17 US US11/873,841 patent/US7915275B2/en active Active
-
2009
- 2009-03-23 CY CY20091100319T patent/CY1108909T1/el unknown
- 2009-04-09 CY CY20091100414T patent/CY1108964T1/el unknown
-
2010
- 2010-11-19 JP JP2010259452A patent/JP2011057698A/ja not_active Withdrawn
- 2010-11-19 JP JP2010259453A patent/JP5635376B2/ja active Active
-
2011
- 2011-03-04 US US13/041,348 patent/US8404704B2/en active Active
- 2011-03-04 US US13/041,346 patent/US8173801B2/en active Active
- 2011-06-23 AR ARP110102194A patent/AR081992A2/es not_active Application Discontinuation
- 2011-06-23 AR ARP110102193A patent/AR081991A2/es not_active Application Discontinuation
-
2014
- 2014-07-04 JP JP2014138697A patent/JP2014177500A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR043547A1 (es) | Formas polimorficas de rifaximina, procesos para su produccion y uso de las mismas en preparaciones medicinales | |
JP2022003052A (ja) | リファキシミン | |
RU2007136430A (ru) | Новые полиморфные формы рифаксимина, способы их получения и их применение в лекарственных препаратах | |
ES2621557T3 (es) | Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas | |
US2984686A (en) | 6-deoxy-6-demethyl-6-methylene-5-oxytetracyclines | |
CN103145636B (zh) | 一种1,4-二酰基-3,6-二苯基-1,4-二氢均四嗪类化合物及其制备方法和应用 | |
CA1303028C (en) | Metal complexes of n-methyl-11-aza-10-deoxo-10- dihydroerythromycina or 11-aza-10-deoxo-10- dihydroerythromycin a, method for the manufacture thereof and their use in the manufacture of pharmaceuticals | |
WO2006035291A1 (en) | Crystalline forms of cefdinir potassium | |
WO2012060675A1 (es) | Proceso para la preparación de rifaximina amorfa | |
CN103450310A (zh) | 豆甾醇衍生物及其在制备抗癌药物中的应用 | |
JP6883593B2 (ja) | 9−アミノメチル基置換のテトラサイクリン系化合物の結晶型及びその製造方法 | |
FI62311B (fi) | Foerfarande foer framstaellning av kristallint natrium- och kaiumcefalexinmonohydrat | |
CN108610347B (zh) | 一种多羰基取代六元半瓜环的化合物及其制备方法 | |
CA2975022C (en) | Polymorphic forms of minocycline base and processes for their preparation | |
CN106187799B (zh) | 一种制备dl-赖氨酸盐酸盐的方法 | |
CN106798739B (zh) | 一种用于治疗肿瘤疾病的药物 | |
CN105198834B (zh) | 2,6‑二溴苯并噻唑的合成工艺 | |
JPS606957B2 (ja) | 抗生物質誘導体の製造方法 | |
CN104262336B (zh) | 一种黄藤素酰腙类衍生物及其制备方法和用途 | |
CN106800538B (zh) | 一种苯并咪唑衍生物及其合成方法 | |
CN104628820B (zh) | 普那霉素ia晶型及其制备方法 | |
CN104130164B (zh) | 外消旋体紫草素萘茜母核羟基甲基化磺酸钠衍生物 | |
CN109575053A (zh) | 一种锌配合物及其制备方法 | |
CN112940017A (zh) | 一种含有锌螯合物的水凝胶材料 | |
JPH03170485A (ja) | 新規なオキサゾピロロキノリン化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure | ||
FC | Refusal | ||
FC | Refusal | ||
FC | Refusal |